Covance Clinical Research Unit Ltd
Leeds, LS2 9LH, United Kingdom
NCT Number: NCT02408055
A study to measure the absorption, metabolism and excretion of a single dose of radiolabelled TA-8995 (10mg) in healthy male subjects.
Looking for future studies?
Notify Me30 year–65 year
Male
Interventional
Phase 1
Leeds, LS2 9LH, United Kingdom
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 35 days
Time frame: 35 days
Time frame: 35 days
Time frame: 35 days
Time frame: 35 days
Time frame: 35 days
Xention Ltd
Industry
A Phase I Study to Assess the Mass Balance Recovery, Pharmacokinetics, Metabolism and Excretion of 14C-TA-8995 in Healthy Male Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07655960
Dyslipidemia, Dyslipidemias
Seoul, South Korea
View Trial DetailsNCT07691268
Dyslipidemia, Dyslipidemias
Seoul, Gwanak-gu 08779, South Korea
View Trial DetailsNCT07627555
Cardiovascular Diseases, Dyslipidemia
Lahore, Pakistan
View Trial DetailsNCT00001154
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyslipidemia
Bethesda, Maryland, United States
View Trial Details